R Is Hydrogen Or A Lower Saturated Alkyl Of Less Than Seven Carbons Patents (Class 514/629)
-
Publication number: 20100249237Abstract: A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, or acetaminophen is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods.Type: ApplicationFiled: June 9, 2010Publication date: September 30, 2010Inventors: Cathy K. Gelotte, Douglas R. Hough, Gerard P. McNally
-
Publication number: 20100239666Abstract: The invention relates to a process for producing mouldings by injection moulding the steps in the process being a) melting and mixing of a (meth)acrylate copolymer composed of from 85 to 98% by weight of C1-C4-alkyl (meth)acrylates capable of free-radical polymerization and from 15 to 2% by weight of (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, with from 10 to 25% by weight of a plasticizer, and also from 10 to 50% by weight of a dryers [sic] and/or from 0.1 to 3% by weight of a release agent, and, where appropriate, with other conventional pharmaceutical additives or auxiliaries and/or with an active pharmaceutical ingredient, b) devolatilizing the mixture at temperatures of at least 120° C., thus reducing the content of the low-boiling constituents with a vapour pressure of at least 1.9 bar at 120° C. to not more than 0.5% by weight, and c) injecting the devolatilized mixture at a temperature of from 80 to 160° C.Type: ApplicationFiled: June 3, 2010Publication date: September 23, 2010Inventors: Hans-Ulrich Petereit, Thomas Beckert, Manfred Assmus, Wemer Hoess, Wolfgang Fuchs, Hartmut Schikowsky
-
Publication number: 20100239638Abstract: A soft capsule in which a shell is filled with fill material, and the fill material is in a solid or semi-solid form at room temperature. The soft capsule may be a chewable capsule, and the fill material may comprise a low melting point additive. The content of the low melting point additive may be 10% or more with respect to the total weight of the fill material, and may have a melting point of about 20 to 50° C. The low melting point additive may be selected from the group consisting of chocolate base, lard, coconut oil and macrogol (polyethylene glycol) as well as a combination thereof.Type: ApplicationFiled: June 11, 2010Publication date: September 23, 2010Inventors: Hidekazu Shodai, Noboru Nagafuji, Toshitada Toyoda, Yuka Okada
-
Publication number: 20100240761Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: ApplicationFiled: May 24, 2010Publication date: September 23, 2010Applicant: DEY, L.P.Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
-
Publication number: 20100239552Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.Type: ApplicationFiled: March 16, 2010Publication date: September 23, 2010Applicant: GENMEDICA THERAPEUTICS SLInventors: Eric Mayoux, Luc Marti Clauzel, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Alec Mian
-
Publication number: 20100233278Abstract: Provided is a solid preparation which rapidly disintegrates in the presence of saliva or a small amount of water in the oral cavity, particularly, a rapidly disintegrating solid preparation useful as an orally-disintegrating solid preparation. Specifically provided is a rapidly disintegrating solid preparation containing coated granules wherein saccharide or sugar alcohol having an average particle size of not less than 75 ?m and a high dissolution rate is coated with cellulose, and a rapidly disintegrating solid preparation containing a) an active ingredient, b) saccharide or sugar alcohol having an average particle size of not less than 400 ?m, c) cellulose and d) a disintegrant.Type: ApplicationFiled: September 26, 2008Publication date: September 16, 2010Inventors: Akiko Ookawa, Yasushi Imada, Yasunari Shinkai, Hideaki Matsumoto
-
Publication number: 20100234472Abstract: The present invention particularly relates to novel nitrate esters of paracetamol. The nitrate esters of paracetamol are prepared by reacting the paracetamol with dihaloalkyl compound and followed by reaction with silver nitrate to obtain the corresponding nitrate ester derivatives. The nitrate esters of paracetamol are useful as analgesic, anti-inflammatory agents.Type: ApplicationFiled: February 17, 2010Publication date: September 16, 2010Inventors: Tilak Raj BHARDWAJ, Manoj Kumar, Neeraj Mehta, Neelima Dhingra
-
Publication number: 20100227811Abstract: The present invention concerns farnesylamine derivatives, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of ras-mediated signal transduction and inhibitors of aberrant cell growth, e.g., as anti-cancer agents, as well as anti-fungal agents. Other non-malignant diseases characterized by proliferation of cells that may be treated using the farneylamine derivatives of the include, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.Type: ApplicationFiled: May 14, 2008Publication date: September 9, 2010Applicant: University of South FloridaInventors: Ravi Kothapalli, Kirpal S. Bisht
-
Publication number: 20100226945Abstract: A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods.Type: ApplicationFiled: May 18, 2010Publication date: September 9, 2010Inventor: Gail K. Buehler
-
Publication number: 20100226964Abstract: The present invention relates to solid dispersions including, but not limited to, co-processed carbohydrates with different solubilities and concentrations, which have a microcrystalline plate structure. The solid dispersions, excipient systems and formulations of the present invention are highly compactable and durable and when compressed into solid dosage forms demonstrate uniform densification, low friability at low pressures, and/or relatively constant low disintegration times at various hardnesses. The solid dosage forms of the present invention demonstrate superior organoleptics, disintegration, and/or robustness.Type: ApplicationFiled: March 9, 2010Publication date: September 9, 2010Applicant: SPI Pharma, Inc.Inventors: John Tillotson, Cecil Propst
-
Publication number: 20100222298Abstract: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.Type: ApplicationFiled: May 13, 2010Publication date: September 2, 2010Applicant: Taro Pharmaceuticals U.S.A., Inc.Inventors: Satish ASOTRA, Xiaoli WANG, Zoltan BODOR
-
Publication number: 20100221351Abstract: In accordance with certain embodiments of the present disclosure, A method for intracellular delivery of cytotoxin in combination with cyoablation is provided. The method includes encapsulation of one or more cytotoxins in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule whereby the one or more cytotoxins are sucked into or diffuse into the nanocapsule. The temperature of the nanocapsule is increased and the nanocapsule is delivered into a cell. Cryoablation is performed in proximity to the cell resulting in the release of the one or more cytotoxins from the nanocapsule into the cell.Type: ApplicationFiled: March 1, 2010Publication date: September 2, 2010Applicant: UNIVERSITY OF SOUTH CAROLINAInventor: Xiaoming He
-
Publication number: 20100210524Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are as defined in the specification. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.Type: ApplicationFiled: July 21, 2008Publication date: August 19, 2010Inventors: Theresa Apelqvist, Joakim Löfstedt, Thomas Norin, Mattias Wennerstål, Xiongyu Wu, Lars Hagberg
-
Publication number: 20100203130Abstract: The present invention provides immediate release pharmaceutical compositions for Oral administration that are resistant to abuse.Type: ApplicationFiled: February 5, 2010Publication date: August 12, 2010Applicant: EGALET A/SInventors: Peter Holm Tygesen, Jan Martin Oevergaard, Karsten Lindhardt, Louise Inoka Lyhne-Iversen, Martin Rex Olsen, Anne-Mette Haahr, Jacob Aas Hoellund-Jensen, Pernille Kristine Hoeyrup Hemmingsen
-
Publication number: 20100204259Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol.Type: ApplicationFiled: February 5, 2010Publication date: August 12, 2010Applicant: EGALET A/SInventors: Peter Holm Tygesen, Jan Martin Oevergaard, Joakim Oestman
-
Publication number: 20100197663Abstract: Chronic pain is treated with a combination of a standard dose of a non-narcotic analgesic and a low dose of a tricyclic antidepressant compound. The invention is effective in the treatment of chronic pain associate with neuropathic or fibromuscular disorders, where such pain has been unresponsive to non-narcotic analgesics alone.Type: ApplicationFiled: April 12, 2010Publication date: August 5, 2010Applicant: RODLEN LABORATORIES, INC.Inventor: Joel E. Bernstein
-
Publication number: 20100196466Abstract: A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided.Type: ApplicationFiled: January 29, 2010Publication date: August 5, 2010Applicant: Capricorn Pharma Inc.Inventor: S. Rao CHERUKURI
-
Publication number: 20100196474Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.Type: ApplicationFiled: December 22, 2009Publication date: August 5, 2010Applicant: Depomed, Inc.Inventors: Chien-Hsuan Han, Sui Yuen Eddie Hou, Monica L. Reid
-
Publication number: 20100196425Abstract: A sustained release dosage form is provided comprising a pharmaceutically active agent and pharmaceutically acceptable salts thereof and adapted to release as an erodible solid over a prolonged period of time, wherein the dosage form provides burst release of the pharmaceutically active agent without the use of an immediate release drug coating. The dosage form is able to deliver high doses of poorly soluble or slowly dissolving active agents at a controlled rate. Methods of using the dosage forms to treat disease or conditions in human patients are also disclosed.Type: ApplicationFiled: January 6, 2010Publication date: August 5, 2010Inventors: Evangeline Cruz, Sherry Li, Atul D. Ayer, Brenda J. Pollock, Gregory C. Ruhlmann, Carmelita Garcia, Alfredo M. Wong, Lawrence G. Hamel
-
Publication number: 20100184861Abstract: The invention provides, inter alia, a method for producing granules from a powder, characterized in that compaction force is applied to the powder to produce a compacted mass comprising a mixture of fine particles and granules and separating and removing fine particles and/or small granules from the other granules by entraining the fine particles and/or small granules in a gas stream. Also provided are apparatus for use in the process and tablets formed by compression of the resultant granules.Type: ApplicationFiled: October 16, 2009Publication date: July 22, 2010Inventors: Giovanni Politi, Erkki Heilakka
-
Publication number: 20100183712Abstract: The present invention relates to acylated indanyl amines according to the general formula (I) wherein R1-R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1-C3-alkyl), B is CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description.Type: ApplicationFiled: March 29, 2010Publication date: July 22, 2010Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Hartmut STROBEL, Paulus WOHLFART, Alena SAFAROVA, Armin WALSER, Teri SUZUKI, Karl SCHÖNAFINGER, Ramalinga M. DHARANIPRAGADA
-
Publication number: 20100172974Abstract: Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.Type: ApplicationFiled: March 12, 2010Publication date: July 8, 2010Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang
-
Publication number: 20100173876Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.Type: ApplicationFiled: July 30, 2009Publication date: July 8, 2010Applicant: The Board of Regents of the University of Texas SystemInventors: Lenard M. Lichtenberger, Shiqiang Tian
-
Patent number: 7749526Abstract: Compounds of formula (I) are described for deterring vermin, wherein R is unbranched or branched C1-C15 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; R1 and R2 are unbranched or branched C1-C12 alkyl, preferably C1-C6 alkyl, which is unsubstituted or substituted by halogen, cyano or nitro; and X and Y, independently of one another, are a straightchain or branched alkylene bridge with 1 to 20 carbon atoms, preferably an alkylene bridge with 1 to 3 carbon atoms, which is unsubstituted or substituted by halogen, cyano or nitro. Furthermore, an essentially non-therapeutical process for deterring vermin is described, which is based on the usage of these compounds, as well as verminrepellent compositions containing these compounds as the active ingredient, and finally the use of these compounds for producing vermin-deterring compositions and their usage in deterring vermin from animals, humans and objects. New compounds within the scope of formula (I) are also described.Type: GrantFiled: December 16, 2003Date of Patent: July 6, 2010Assignee: Novartis AGInventors: Thomas Goebel, Tania Cavaliero, Jacques Bouvier
-
Publication number: 20100168074Abstract: A freezable unit dosage delivery system, method of preparation, a solid unit dosage, method of treating symptoms and conditions, and kit is disclosed. The freezable unit dosage delivery system includes a composition, preferably containing one or more medicinal ingredients, having a freezing point less than 5° C.; a storage container comprising one or more cavity, each configured to receive a unit dosage quantity of the composition; and a sealing sheet for sealing engagement with the storage container. Upon freezing, the unit dosage quantity solidifies into a solid unit dosage that may be administered one of orally, rectally or vaginally for the local or systemic treatment of symptoms and conditions in a human.Type: ApplicationFiled: April 11, 2008Publication date: July 1, 2010Inventors: Christopher Culligan, Neil Smith, Rob Hart, Jay Sankey
-
Publication number: 20100167926Abstract: The present invention relates to 3-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the phenoxyamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.Type: ApplicationFiled: March 4, 2008Publication date: July 1, 2010Applicant: Bayer CropScience AGInventors: Klaus Kunz, Ralf Dunkel, Jorg Nico Greul, Kerstin Ilg, Birgit Kuhn, Wahed Ahmed Moradi, Thomas Seitz, Darren James Mansfield, Oliver Guth, Peter Dahmen, Ulrike Wachendorff-Neumann, Arnd Voerste, Robert Dale Mitchell, Tom Hough
-
Publication number: 20100152298Abstract: This invention helps in the treatment and the management of cancer. It is the use of flutamide drug to treat and manage cancer where the Flutamide anti-androgen drug acts in another mechanism other than the well know androgen respects (AR) mechanism.Type: ApplicationFiled: February 12, 2008Publication date: June 17, 2010Applicant: UNIVERSITY OF KUWAITInventor: Fatma Jassab Faleh Al-Saeedi
-
Publication number: 20100150838Abstract: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.Type: ApplicationFiled: December 24, 2009Publication date: June 17, 2010Inventors: Shari M. Ling, Lorah Perlee, Velizar T. Tchernev, Serguei Lejnine, Dhavalkumar D. Patel, Luigi Ferrucci, Ming Zhan
-
Publication number: 20100152272Abstract: Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH2 are biologically active compounds; each X is independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone moiety), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO—, where y is 2-4 or 6-24 and —(CH2CH2O)zCH2COO—, where z is 2-24; each Y is independently selected from —COCH2O— (glycolic ester moiety), —COCH(CH3)O— (lactic ester moiety), —COCH2OCH2CH2O— (dioxanone ester moiety), —COCH2CH2CH2CH2CH2O— (caprolactone ester moiety), —CO(CH2)mO—, where m is 2-4 or 6-24 and —COCH2O(CH2CH2O)n— where n is between 2-24; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.Type: ApplicationFiled: February 17, 2010Publication date: June 17, 2010Applicant: BEZWADA BIOMEDICAL, LLCInventor: Rao S. Bezwada
-
Patent number: 7736626Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.Type: GrantFiled: June 20, 2007Date of Patent: June 15, 2010Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Christel Schmelzer
-
Patent number: 7736627Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.Type: GrantFiled: October 22, 2007Date of Patent: June 15, 2010Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventor: Christel Schmelzer
-
Patent number: 7732641Abstract: A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.Type: GrantFiled: December 5, 2008Date of Patent: June 8, 2010Assignee: Sepracor Inc.Inventors: Gerald J. Tanoury, Chris H. Senanayake, Donald W. Kessler
-
Patent number: 7714025Abstract: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN—COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an ?,?-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.Type: GrantFiled: May 3, 2007Date of Patent: May 11, 2010Assignee: Arizona Biomedical Research CommissionInventors: Seth D. Rose, Rosemarie F. Hartman
-
Publication number: 20100112054Abstract: The present invention includes systems, compositions and methods of making a multilayer modular release system, wherein the layers form a stack of active agent release layers, wherein the stack comprises a body and first and second ends and an impermeable coating surrounding the body of the stack, wherein the active agent is only release from the first, second or both the first and second ends of the stack by diffusion.Type: ApplicationFiled: October 23, 2009Publication date: May 6, 2010Applicant: APPIAN LABS, LLCInventors: Nicholas A. Peppas, Lisa Peppas
-
Publication number: 20100104638Abstract: An extended release oral administered dosage form of acetaminophen and tramadol. The dosage form includes a composition of acetaminophen together with a tramadol complex formed with an anionic polymer. The tramadol complex provides sustained release of tramadol for a synchronized (coordinated) release profile of acetaminophen and tramadol.Type: ApplicationFiled: October 23, 2009Publication date: April 29, 2010Inventors: WEI-GUO DAI, LIANG-CHANG DONG, TAE-HONG CHOI, SUNG JOO HWANG, JAE HYUN KIM, DONG HO LEE
-
Publication number: 20100104620Abstract: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is defined by compressible excipients. By chewing the product, the medicament or agent is released from the product within the buccal cavity.Type: ApplicationFiled: January 4, 2010Publication date: April 29, 2010Applicant: WM. WRIGLEY JR. COMPANYInventors: Ronald L. Ream, Leonard Matulewicz, William J. Wokas
-
Publication number: 20100099731Abstract: In various embodiments, the present invention relates generally to methods of treating at least one neurodegenerative disease by administering a medicament comprising an endothelial interrupter.Type: ApplicationFiled: September 30, 2009Publication date: April 22, 2010Applicant: Texas Tech University SystemInventors: Paula Grammas, Randolph B. Schiffer
-
Publication number: 20100093710Abstract: A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.Type: ApplicationFiled: December 19, 2007Publication date: April 15, 2010Inventors: Philippe Perovitch, Marc Maury
-
Publication number: 20100086495Abstract: The present invention provides transmucosal pharmaceutical or nutraceutical compositions and methods for enhancing transmucosal delivery of pharmaceutical and nutraceutical ingredients through use of methylsulfonylmethane (MSM) as a transmucosal delivery enhancer. In particular, the invention provides transmucosal compositions comprising an active agent selected from a non-steroid anti-inflammatory drug (NSAID); an analgesic; a migraine medication; a menopause medication; a sleep disorder medication; an erectile dysfunction medication, an appetite suppressant, a vitamin, a food supplement and a macromolecule. In certain particular exemplary formulations the appetite suppressant is DL-phenylalanine, and the vitamin is B12.Type: ApplicationFiled: February 14, 2008Publication date: April 8, 2010Applicant: DERMA-YOUNG LTD.Inventor: Yosef Rubinstein
-
Publication number: 20100087402Abstract: The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression. Intravaginal delivery maximizes local inhibition of estrogen production without significantly affecting systemic circulating estrogen levels. This results in enhanced clinical efficacy and reduced side effects.Type: ApplicationFiled: September 29, 2009Publication date: April 8, 2010Applicant: Vivus, Inc.Inventors: Changjin Wang, Leland F. Wilson
-
Patent number: 7691871Abstract: The invention relates to an improved pharmaceutical or dietary composition in form of an aqueous syrup, consisting essentially of (a) vitamins recommended for consumption by children or young adults, (b) a suitable calcium source, (c) at least one dibasic amino acids, (d) taurine, (e) at least one solubilizer, (f) at least one additional agent selected from the group consisting of sweetening agents, flavoring agents, flavor enhancers, preservatives, antioxidants, co-solvents, and (g) water.Type: GrantFiled: August 16, 2004Date of Patent: April 6, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Fabrizio Camponovo, Fabio Danini
-
Publication number: 20100080847Abstract: This invention relates to a medicinal composition, which rapidly disintegrates when taken in the oral cavity and shows sufficient hardness upon production, distribution and use in usual manner, can be obtained by adding, to a sugar alcohol and/or saccharide, a sugar alcohol and/or saccharide having a lower melting point than the first-mentioned sugar alcohol and/or saccharide and then subjecting the resulting powder to combined processing of compression and heating. This invention can provide medicinal compositions, which rapidly disintegrate when taken in the oral cavity without water and are excellent in handling ease owing to exhibition of sufficient hardness upon their production, transportation and use in usual manner, and can also provide a process for the production of the medicinal compositions, which is simpler and can avoid contact between an active ingredient and water as needed.Type: ApplicationFiled: December 4, 2009Publication date: April 1, 2010Applicant: DAIICHI PHARMACEUTICAL CO., LTD.Inventors: Hiroaki Nakagami, Yoshio Kuno
-
Publication number: 20100069485Abstract: A process and a composition to extend the freshness of fruits and vegetables are disclosed. The method comprises treating fresh fruit or vegetable structures with a solution comprising organic acids including N-acetyl cysteine.Type: ApplicationFiled: April 25, 2006Publication date: March 18, 2010Inventors: John Xianrong Liu, Virginia Margarita Fraga, Thomas Young
-
Publication number: 20100069501Abstract: A combination comprising (a) at least one 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol component, and (b) Paracetamol or a derivative thereof; a pharmaceutical composition and/or dosage form comprising such a combination as well as a method of treating one or more of pain and ostheoarthritis in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to said mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: September 4, 2009Publication date: March 18, 2010Applicant: GRUENENTHAL GmbHInventors: Petra Bloms-Funke, Klaus Schiene
-
Publication number: 20100063157Abstract: The present invention relates to the preparation of a ?2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I) in particular a crystalline monohydrochloride salt. The invention also relates to a new crystalline form (polymorph) of the monohydrochloride salt of compound (Ia) and a process for preparing it.Type: ApplicationFiled: March 30, 2005Publication date: March 11, 2010Inventor: Darren Michael CAINE
-
Publication number: 20100063010Abstract: A method for administering a spill-resistant pharmaceutical formulation comprises delivery from a squeezable container of a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent.Type: ApplicationFiled: October 22, 2009Publication date: March 11, 2010Applicant: Taro Pharmaceutical Industries Ltd.Inventors: Rakesh MEHTA, Dan Moros
-
Patent number: 7655700Abstract: The present invention describes a transgenic mouse susceptible to neuromuscular disease. The present invention also includes methods for treatment of neuromuscular diseases by interfering with activity between androgen and androgen receptors exclusively in the muscle fibers.Type: GrantFiled: August 24, 2006Date of Patent: February 2, 2010Assignee: Michigan State UniversityInventors: Cynthia Jordan, Douglas A. Monks, Marc Breedlove
-
Publication number: 20100022588Abstract: The present invention relates to a pharmaceutical carrier composition and a pharmaceutical composition comprising said pharmaceutical carrier composition. The pharmaceutical composition comprises: (a) at least 20% (w/w) of the composition of a sugar or a sugar alcohol; (b) one or more pharmaceutically acceptable excipients; (c) one or more pharmaceutically active ingredients in their base form; and (d) water up to 100% (w/w). The present pharmaceutical composition is especially resistant against flocculation, clumping and/or precipitation at room temperature during prolonged time-periods such as one or more years.Type: ApplicationFiled: February 13, 2008Publication date: January 28, 2010Inventor: Frans Herwig Jansen
-
Publication number: 20100016677Abstract: A method of influencing a physiological condition of a physiological subject, the method comprising detecting a workload distribution/activity in a brain of the physiological subject, the workload distribution/activity being indicative of the physiological condition, and selectively modifying the workload distribution/activity in the brain of the physiological subject to thereby modify the physiological condition.Type: ApplicationFiled: March 20, 2007Publication date: January 21, 2010Inventors: Eugen Oetringer, Kevin Doyle
-
Patent number: RE41278Abstract: Compositions comprising N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl compounds are useful to alleviate or improve various cosmetic conditions and dermatological disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors. N-acetyl-aldosamines, N-acetylamino acids, and related N-acetyl composition may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.Type: GrantFiled: November 1, 2006Date of Patent: April 27, 2010Inventors: Ruey J. Yu, Eugene J. Van Scott